Joseph K. Belanoff
Charlie. you, Thank
our high of more another the our and reflect in to changing record awareness third A This led Our more harm has Korlym. the physicians increasing hypercortisolism screening physicians of prescribe common, behavior in becomes results it disease revenue. receive patients quarterly more and quarter strong causes.
provide an We to expect have are for treatment large eligible turn syndrome currently this is CATALYST growth syndrome goes treatment there was of study results once undiagnosed to lead believe patients group with with will patients and yet belief, that whose patients in endocrinologists in trend this physicians in Cushing's many thinking and medical it. practice syndrome excellent business. The evidence effective our to Cushing's assumed. it, are our to and of further more .
Korlym medical increasingly which for Leading our the patients than with continue. will who this considerably bolster receive there indensify hypercortisolism commercial and Cushing's advance likely provide
powerful revenue again our disorders. $XXX by many therapeutic development range development million built is efforts time excited also We're of are raising modulation a our inception, million. potential serious this to in hypothesis, the clinical Since the $XXX to cortisol the XXXX mechanism have We our and programs. research on very
not modulate compounds receptor proprietary activated our high. glucocorticoid receptor progesterone specs approved most product, GR, some the cortisol to They off-target Our the is to and Korlym's are of receptor effects. binding levels serious bind do cost by or which cortisol and the don't
the cortisol blood all others barrier, not. they some while Interestingly, compounds produce our distinct brain clinical modulate activity, effects do cross
solid of tumors. models metabolic perform of more Others models best disease. potent are Some in
more Some global be have events Others appear specific, tissue to
cortisol variety These programs allow Dazaorland and ovarian, qualities of disorders. wide in of course, and adrenal selective to Cushing's prostate proprietary are miricorilant X NASH study with us a we modulators, ALS, of and, syndrome. Currently, relacorilant, our cancer conducting diverse
XXXX, are Catalyst, late-stage study. our and Grace, DAZALS Additional clinical GRADIENT, are milestones approaching. of from development. compounds ROSELLA in earlier data Important In we expect stages development
and plan enrollment MONARCH an relacorilant to Phase our also IIb study to NDA of submit complete We syndrome patients NASH. in with for
very exciting This is a time Corcept. for
the cortisol effect Relacorilant relacorilant III Phase it Like selective cortisol evaluating are a with GRACE at and glucocorticoid receptor. the trials, by We Korlym, GRADIENT. of achieves X for in is hypercortisolism modulator. treatment its competing
other to safety data experienced in not and as efficacy Patients signs Phase receptor compelling. not effects. Cushing's the bind does it the does Relacorilant's progesterone-related and so meaningful and improvements Korlym, II symptoms control glucose of and side well syndrome. were in hypertension progesterone Unlike as cause
instances There a were of New results progesterone-related cause hypokalemia, The in Frontiers leading and endocrinology of II in no effects were side continuation. published bleeding, in thickening endometrial XXXX. Journal trial vaginal or Phase no relacorilant-induced July drug-induced
patients has finishing We preparing available. are treatment GRACE are our all trial focused submit to which promise a and plan on of of we our the endogenous syndrome, as XXXX. tremendous make quarter Cushing's for we ologies it second and with NDA, to eager Relacorilant
Cushing's caused by in adrenal studying is an is III trial GRADIENT patients adenoma or relacorilant adrenal second Phase Our hypercortisolism, whose hyperplasia. effects in syndrome
of death. often this less are poor, geology with higher experience significantly Patients to premature outcomes their rapid health Cushing risk a syndrome a decline, but including
not of syndrome about our valuable many depend etiology syndrome While GRADIANT, Cushing’'s the expect to we patients. the data NDA Cushing's of from data on we treatment do in that do to produce study expect affects
prevalence diabetes IV to in conducted diabetes. that than Phase the type years with in hypercortisolism general CATALYST in Our control the with substantially found Many is patients largest have difficult establish of independent higher XX is of trial the to population. studies hypercortisolism study conducted patients X prevalence the ever over the last
Cushing’ in the in diabetologists participating the catalysts, syndrome. prominent in to has helped become are which potential design most United us and understanding landmark guiding The a States of physicians'
next from We prevalence CATALYST study phase year. early of the the expect data
cancer, by the chemotherapy selective of in Our effect beneficial postulated Cortisol successful later enhance Phase by in effect suppressing. investigators the of One modulator of of prominent induce against increasing Chicago the effect. meant oncology addition chemotherapy likely controlled our death trial confirmed II is to works program platinum-resistant In cell other anti-apoptotic apoptisis mechanisms, program with by mechanism cortisol tumors. first solid by cortisol's anticancer ovarian at relacorilant, researchers. X our is University testing is blunting the women the and chemotherapy
Relacorilant to of study. the provided a meaningful benefit women our in many
day or X these relacorilant previous had chemotherapy's women's treatment, their and nab-paclitaxel beneficial the the to who lines intermittently, statistically Those improvement nab-paclitaxel of the including received disease group compared received day the exhibited appear of progression-free response taxanes, While to relacorilant of to received they and more previous monotherapy. progressed before, survival tumors who resensitize effects. duration after a significant in on day
with of who who took arm intermittent approached also X of patients took years the than of XX% Women in that the comparator statistical those after intermittent natpaclitaxel alive significance. longer were those XX% live relacorilant relacorilant group p-value a only study the alone. versus start
as received alone. burden important, received women effect relacorilant additional Just who the plus experienced side who nab-paclitaxel compared those no nab-paclitaxel to
Oncology The the the the of of in June were published Journal Oncology, been of XXXX XXXX year, Clinical of Meeting. Medical Annual presentations and Clinical at Oncology, Society featured in ESMO this have this ASCO for European Society meetings podium XXXX also results results and from at American study in
II our our II plus ROSELLA's in trial cancer simply III receive patients. larger results either in Phase ROSELLA, group. a or women enrolling Phase replicate Planned our pivotal nab-paclitaxel XXX Phase goal tracks to closely multinational nab-paclitaxel to relacorilant ovarian is randomized is X:X platinum-resistant enrollment ROSELLA's alone. positive study. designed
secondary with endpoint a survival, key primary endpoint. progression-free The is survival overall
Europe. collaboration Group the in Gynecological States conducting in from Oncology in and Oncology are the study Group We Gynecological this clinicians leading with United Trials Euro the of Network
of potential relacorilant data has without gynecological effect improved benefit next and a We medical ovarian to care year. women constitute oncologists the platinum-resistant an new told progression-free of burden. us by and Leading important survival end in expect standard cancer. potential that side the become relacorilant's nab-paclitaxel We increased overall have the advance with plus
cancer will is experienced androgen is important cortisol androgen of is enzalutamide, stimulate with reason close A therapy prostate activity disease. pathway. adding antagonist second cortisol modulation may deformation hypothesis a that mechanism event a prove receptor androgen widely their -- this treated why Cortisol to resurgent blocking prescribed by tumor switch to tumor an a tumor modulator by with major The growth pride to which cortisol route. stimulation, stimulation escape our patients useful
treat these have randomized the Chicago response. the the trial third at initiated University to enzalutamide the patients seeks patients therapies collaborators prostatectomy. plus tumors system. A system, in Cortisol placebo-controlled with immune suppresses prostate immune which effectiveness body's initial of immune stimulate therapeutic before may II of the had of cancer enhancing Phase relacorilant by Our an cancer have to a intended mechanism blunt
may a Our therapies. those checkpoint as enhance hypothesis the is immunotherapies effectiveness of that modulator adding to such inhibitors, cortisol
whose is pembrolizumab, advanced treating in are this tumors cancer We relacorilant a of plus patients the affected in produce inhibitor, cancer. cortisol. Ib with adrenal monotherapy excess rarely adrenal as Phase PD-X form Pembrolizumab conducting of checkpoint trial
a shown that DAZALS, of placebo-controlled great ALS, Dazacorilan disease patients ALS enrolling promise improving treatment. ALS, commonly is devastating known atrophy. of trial is urgent patients briskly. illness for muscular selective need and cortisol modulator an double-blind motor a models in reducing neuroinflammation is has performance animal with our dasicorilant with randomized II XXX-patient better in as Phase and
and Europe United in We sites States. the are important conducting this study at
end expect the We year. data by of next
our Finally, In as demonstrate of States., treatment liver to elevations serious of AST. exhibited program liver study, ALT disorder continues our who in NASH afflicts great I'll liver or that XXX an NASH, prior large a albeit fat, milligrams the substantial for but transient patients daily of oral promise also NASH. in rapid United a turn reductions in miricorilant received to XXX millions patients milligrams medication and the enzymes,
occurred The and more is seen greater treatment. improvement any period in liver expected rarely and had than fat over in rapidly we these of was patients much
markers Ib XX liver and an of miricorilant twice just fat week patients who of milligrams improvements Phase liver study in Our dose-finding and for approximately reduction XX% a showed XXX that liver disease. found received experienced in enzymes weeks orally
key in improvements experienced HOMA-IR, and lipid triglycerides such serum also patients and as metabolic LDL. measures These
Importantly, no apparent with GI very side effects. well tolerated was miricorilant
our We intend of NASH. double-blind upcoming results Phase placebo-controlled in randomized promising AASLD of Phase XXX-patient on MONARCH the Ib our meeting build to Boston. We will with trial biopsy-confirmed the these results with present at miricorilant patients study IIb in
the Since is of endpoints. XXX XX placebo endpoint fat resolution and NASH weeks. will or twice The in fibrosis improvement with as or miricorilant liver receive weekly primary secondary either key milligrams reduction
the conclusion, extremely we are about In of cc. future optimistic
development invest as Our Kirstin our syndrome programs. advancing business we has profits even substantial and in tremendous generate growth potential
We years our growth and for guidance XXXX revenue to raising come. are again anticipate
will study hypercortisolism, is population treat CATALYST physicians caused frequently Data undiagnosed. patients whose identify difficult by and from large goes diabetes to syndrome Cushing's control better help our too whose a
potential the Our programs wide has range of treat diseases. are evidence modulation a development generating increasing cortisol that to
cancer, be and ovarian There examples. others. syndrome, current cancer, Cushing's will prostate NASH are ALS
selective proprietary in modulators different our with very clinical attributes. more many have potentially portfolio We cortisol
Gradient and advance will these data we cancer in to Cushing's Rosella of most in trial DASL the We In expect in and XXXX, Grace, studies clinic. ovarian our our pivotal ALS. the from promising CATALYST study syndrome,
in enrollment complete and We IIb in an expect NASH. MONARCH for to study submit Phase to relacorilant in CushING NDA our syndrome
As I time for it have said, is an Corcept. exciting
today. team, want day look member therapeutic Markets, of President moment executive We at Before introduce NASH. Monica ALS Corcept. whose I newer will we newest as for as such a the Corcept contributions. our take is to her responsible be questions, to Toledo, take our Emerging forward first Monica, to to of and Monica, welcome areas
to now questions. proceed Let's
